Photodynamic Therapy With Verteporfin in Subfoveal Choroidal NeovascularizationSecondary to Central Serous Chorioretinopathy

Abstract

Objective: To examine the efficacy and safety of photodynamic therapy with verteporfin in the treatment of subfoveal choroidal neovascularization secondary to central serous chorioretinopathy (CSC).Design: Prospective interventional, noncomparative case series.Methods: After the diagnosis of a subfoveal choroidal neovascularization secondary to CSC, 26 eyes of 24 patients were treated with photodynamic therapy with verteporfin. Patients were then followed up every 2 to 3 months, with further treatments performed as deemed necessary through fluorescein angiography. The mean observation was 22.2 months (range, 6-36 months; median, 24 months).Results: There was marked visual improvement, with patients gaining a mean of 1.6 lines after 1 year and a mean of 2.2 lines after 2 years. There was a statistically significant change in visual acuity from baseline to 12 and 24 months (mean difference, -0.16, P=.03; and mean difference, -0.22, P=.02; respectively; t test for both). There was no correlation between patients' age or greatest linear dimension of the lesions and the final outcome (PϾ.10 for all). No patient experienced any adverse effects.Conclusion: Photodynamic therapy with verteporfin resulted in a beneficial outcome in the treatment of subfoveal choroidal neovascularization secondary to CSC, without serious adverse effects in this case series.

Verteporfin PDT for non-standard indications—a review of current literature

“…Encouraging outcomes have been reported from several prospective [29,[33][34][35] and retrospective case series [36,37] in 119 verteporfin-treated eyes with CSCR. The standard regimen of verteporfin PDT was evaluated in two prospective case series [29,35].…”

“…The standard regimen of verteporfin PDT was evaluated in two prospective case series [29,35]. In the first of these studies, ten eyes were identified as having subfoveal or juxtafoveal CNV secondary to CSCR and received verteporfin PDT during a mean of 12.6 months, with six eyes (60%) gaining at least 2 lines of VA and no eye losing 2 lines or more [29].…”

“…In the second study, 26 eyes in 24 patients with CNV due to CSCR were treated with verteporfin PDT and followed up for a mean of 22 months, with additional treatments at 2-to 3-month intervals if required, based on FA [35]. In these patients, VA had improved by 1.6 lines at year 1 and 2.2 lines at year 2.…”

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 1)

“…No patient suffered serious ocular or systemic complications, demonstrating PDT as a safe and well-tolerated treatment in patients with CNV associated with CSCR. Ergun et al [37] performed PDT in 26 eyes with subfoveal CNV secondary to CSCR. The average number of required treatments was 2.6 (range 1–7).…”

25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina

“…This technique has been shown to be effective in certain cases of CNV but is not currently in widespread use. 36 PDT has also been used and shown to be effective in the treatment of choroidal haemangioma, 37 chronic central serous retinopathy, 38 and in polypoidal vasculopathy, where it has been shown to be superior to ranibizumab. 39 Anti-angiogenic agents in AMD Anti-angiogenic therapy has transformed the treatment in wet AMD, with improved visual outcomes over PDT monotherapy, and ranibizumab and bevacizumab are currently the gold-standard care.…”